[1]
Cramer KS, Miko IJ. Eph-ephrin signaling in nervous system development. F1000Research. 2016:5():. pii: F1000 Faculty Rev-413. doi: 10.12688/f1000research.7417.1. Epub 2016 Mar 30
[PubMed PMID: 27092247]
[2]
Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010 Jun 25:141(7):1117-34. doi: 10.1016/j.cell.2010.06.011. Epub
[PubMed PMID: 20602996]
[4]
Wieduwilt MJ,Moasser MM, The epidermal growth factor receptor family: biology driving targeted therapeutics. Cellular and molecular life sciences : CMLS. 2008 May;
[PubMed PMID: 18259690]
[5]
Ornitz DM, Marie PJ. Fibroblast growth factor signaling in skeletal development and disease. Genes & development. 2015 Jul 15:29(14):1463-86. doi: 10.1101/gad.266551.115. Epub
[PubMed PMID: 26220993]
[6]
Tomuschat C, Puri P. RET gene is a major risk factor for Hirschsprung's disease: a meta-analysis. Pediatric surgery international. 2015 Aug:31(8):701-10. doi: 10.1007/s00383-015-3731-y. Epub 2015 Jul 12
[PubMed PMID: 26164711]
Level 1 (high-level) evidence
[8]
Jeanpierre C,Macé G,Parisot M,Morinière V,Pawtowsky A,Benabou M,Martinovic J,Amiel J,Attié-Bitach T,Delezoide AL,Loget P,Blanchet P,Gaillard D,Gonzales M,Carpentier W,Nitschke P,Tores F,Heidet L,Antignac C,Salomon R, RET and GDNF mutations are rare in fetuses with renal agenesis or other severe kidney development defects. Journal of medical genetics. 2011 Jul;
[PubMed PMID: 21490379]
[9]
Chu M, Li T, Shen B, Cao X, Zhong H, Zhang L, Zhou F, Ma W, Jiang H, Xie P, Liu Z, Dong N, Xu Y, Zhao Y, Xu G, Lu P, Luo J, Wu Q, Alitalo K, Koh GY, Adams RH, He Y. Angiopoietin receptor Tie2 is required for vein specification and maintenance via regulating COUP-TFII. eLife. 2016 Dec 22:5():. doi: 10.7554/eLife.21032. Epub 2016 Dec 22
[PubMed PMID: 28005008]
[10]
Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annual review of neuroscience. 2001:24():677-736
[PubMed PMID: 11520916]
[11]
Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, Kawano T, Mitsubuchi H, Tonoki H, Awaya Y, Matsuda I. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nature genetics. 1996 Aug:13(4):485-8
[PubMed PMID: 8696348]
[12]
Shibuya M, Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes
[PubMed PMID: 22866201]
[13]
Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007 Dec 14:131(6):1124-36
[PubMed PMID: 18083102]
[14]
Burden SJ, Yumoto N, Zhang W. The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harbor perspectives in biology. 2013 May 1:5(5):a009167. doi: 10.1101/cshperspect.a009167. Epub 2013 May 1
[PubMed PMID: 23637281]
Level 3 (low-level) evidence
[15]
Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. Journal of cellular biochemistry. 1991 Apr:45(4):319-26
[PubMed PMID: 2045423]
[16]
Knowles PP,Murray-Rust J,Kjaer S,Scott RP,Hanrahan S,Santoro M,Ibáñez CF,McDonald NQ, Structure and chemical inhibition of the RET tyrosine kinase domain. The Journal of biological chemistry. 2006 Nov 3;
[PubMed PMID: 16928683]
[17]
Metzker ML. Sequencing technologies - the next generation. Nature reviews. Genetics. 2010 Jan:11(1):31-46. doi: 10.1038/nrg2626. Epub 2009 Dec 8
[PubMed PMID: 19997069]
[18]
Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature reviews. Cancer. 2007 Mar:7(3):169-81
[PubMed PMID: 17318210]
[19]
El Fakih R, Rasheed W, Hawsawi Y, Alsermani M, Hassanein M. Targeting FLT3 Mutations in Acute Myeloid Leukemia. Cells. 2018 Jan 8:7(1):. doi: 10.3390/cells7010004. Epub 2018 Jan 8
[PubMed PMID: 29316714]
[20]
Kato S,Subbiah V,Marchlik E,Elkin SK,Carter JL,Kurzrock R, {i}RET{/i} Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Apr 15;
[PubMed PMID: 27683183]
[21]
Takeuchi K, Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biological & pharmaceutical bulletin. 2011:34(12):1774-80
[PubMed PMID: 22130229]
[22]
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ. ROS1 rearrangements define a unique molecular class of lung cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Mar 10:30(8):863-70. doi: 10.1200/JCO.2011.35.6345. Epub 2012 Jan 3
[PubMed PMID: 22215748]
[23]
Regad T. Targeting RTK Signaling Pathways in Cancer. Cancers. 2015 Sep 3:7(3):1758-84. doi: 10.3390/cancers7030860. Epub 2015 Sep 3
[PubMed PMID: 26404379]
[24]
Mendes D,Alves C,Afonso N,Cardoso F,Passos-Coelho JL,Costa L,Andrade S,Batel-Marques F, The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review. Breast cancer research : BCR. 2015 Nov 17;
[PubMed PMID: 26578067]
Level 1 (high-level) evidence
[25]
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England journal of medicine. 2009 Apr 2:360(14):1408-17. doi: 10.1056/NEJMoa0805019. Epub
[PubMed PMID: 19339720]
[26]
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jul:25(7):1346-1355. doi: 10.1093/annonc/mdu141. Epub 2014 Apr 8
[PubMed PMID: 24718886]
Level 1 (high-level) evidence
[27]
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J, REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England). 2014 Jan 4:383(9911):31-39. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3
[PubMed PMID: 24094768]
Level 1 (high-level) evidence
[28]
Zhou C,Wu YL,Chen G,Feng J,Liu XQ,Wang C,Zhang S,Wang J,Zhou S,Ren S,Lu S,Zhang L,Hu C,Hu C,Luo Y,Chen L,Ye M,Huang J,Zhi X,Zhang Y,Xiu Q,Ma J,Zhang L,You C, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet. Oncology. 2011 Aug;
[PubMed PMID: 21783417]
Level 1 (high-level) evidence
[29]
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England journal of medicine. 2009 Sep 3:361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19
[PubMed PMID: 19692680]
[30]
Gregorc V, Lazzari C, Karachaliou N, Rosell R, Santarpia M. Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. Translational lung cancer research. 2018 Apr:7(Suppl 2):S165-S170. doi: 10.21037/tlcr.2018.03.19. Epub
[PubMed PMID: 29782558]
[31]
Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. The New England journal of medicine. 2017 Feb 16:376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6
[PubMed PMID: 27959700]
[32]
Peters S,Camidge DR,Shaw AT,Gadgeel S,Ahn JS,Kim DW,Ou SI,Pérol M,Dziadziuszko R,Rosell R,Zeaiter A,Mitry E,Golding S,Balas B,Noe J,Morcos PN,Mok T, Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine. 2017 Aug 31;
[PubMed PMID: 28586279]
[33]
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine. 2018 Feb 22:378(8):731-739. doi: 10.1056/NEJMoa1714448. Epub
[PubMed PMID: 29466156]
[34]
Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. European journal of cancer (Oxford, England : 1990). 2008 May:44(7):946-53. doi: 10.1016/j.ejca.2008.03.006. Epub 2008 Apr 7
[PubMed PMID: 18396036]
[35]
Griffin M, Scotto D, Josephs DH, Mele S, Crescioli S, Bax HJ, Pellizzari G, Wynne MD, Nakamura M, Hoffmann RM, Ilieva KM, Cheung A, Spicer JF, Papa S, Lacy KE, Karagiannis SN. BRAF inhibitors: resistance and the promise of combination treatments for melanoma. Oncotarget. 2017 Sep 29:8(44):78174-78192. doi: 10.18632/oncotarget.19836. Epub 2017 Aug 3
[PubMed PMID: 29100459]